Roadzen Inc. — FY2024 Form 10-K
Reporting period: Fiscal year ended March 31, 2024; this is an annual report, not a standalone 2023 fourth-quarter filing. Amounts are in U.S. dollars unless stated otherwise. Roadzen provides AI-enabled auto-insurance technology and brokerage services. Its September 2023 business combination was accounted for as a reverse recapitalization, with Roadzen (DE) as accounting predecessor. The 2024 results include the acquired U.K. business GIM and U.S. business NAC for much of the year.
Financial performance and liquidity
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $46.7 million | $13.6 million |
| Cost of services | $18.1 million | $5.4 million |
| Gross profit / margin | $28.6 million / 61.2% | $8.1 million / 60.1% |
| Operating loss | $(77.7) million | $(11.5) million |
| Net loss attributable to Roadzen | $(99.7) million | $(14.0) million |
| Adjusted EBITDA (non-GAAP) | $(10.4) million | $(9.9) million |
| Cash used in operating activities | $(15.4) million | $(7.5) million |
Revenue grew 245%, driven by acquisitions, increased insurance distribution, new platform contracts and greater use by existing customers. Brokerage commissions and fees represented 65% of FY2024 revenue; IaaS platform sales represented 35%. Roadzen sold approximately 324,000 policies with $61.8 million of gross written premium, versus approximately 259,000 policies and $38.0 million of premium in FY2023.
The net loss widened substantially. General and administrative expense rose to $65.9 million, including $49.1 million of non-cash RSU expense; total stock-based compensation was $56.3 million. Other significant items included $19.5 million of fair-value losses on financial instruments and a $3.4 million impairment of private-company investments. The filing reports a $2.1 million gain on deconsolidation of subsidiaries. Adjusted EBITDA excludes substantial non-cash and other items and remained negative.
At March 31, 2024, cash and cash equivalents were $11.2 million, plus $0.4 million of restricted cash. Current assets were $49.8 million and current liabilities were $65.7 million. Total debt-related borrowings were approximately $19.5 million; total liabilities were $68.6 million, against a stockholders’ deficit of $10.1 million. The balance sheet also included a $28.8 million forward-purchase-agreement asset; its realization depends on the agreement’s terms and valuation.
Net cash used in investing activities was $6.7 million, including $5.7 million for acquisitions. Financing activities generated $21.6 million, principally from borrowings and preferred-stock proceeds. The company reported a $151.0 million accumulated deficit. The auditor’s report is unmodified but includes a going-concern paragraph; the filing states that substantial doubt exists about Roadzen’s ability to continue as a going concern without additional funding.
Material changes and business developments
- FY2024 revenue increased by $33.2 million year over year, while operating expenses rose to $124.4 million from $25.1 million.
- GIM and NAC were acquired in June 2023, adding U.K. MGA, warranty and claims operations, and U.S. roadside-assistance and claims services. The filing also records acquisition-related activity involving FA Premium Insurance Broking.
- Roadzen deconsolidated three Indian subsidiaries after losing board control; it recorded a $2.1 million gain and provided for certain advances and receivables associated with these entities.
- Customer concentration is significant: two customers represented approximately 29% and 21% of FY2024 revenue; ten customers collectively accounted for approximately 79%.
Outlook, risks and contingencies
- Funding and going concern: Management expects continued operating losses and negative operating cash flows and says additional capital is needed. Post-year-end, it cited term sheets for more than $50 million of potential equity and debt funding, subject to definitive agreements, due diligence and other conditions; availability is not assured.
- Near-term debt pressure: The $7.5 million Mizuho senior secured notes bore 15% interest and were due June 30, 2024. Mizuho granted a waiver through July 31, 2024 while negotiations continued; the filing gives no assurance of an extension or additional funds. The notes are secured by substantially all assets of the loan parties, and the facility includes a minimum $1 million cash-reserve requirement.
- Other expensive financing: The company had short-term and secured borrowings, including debentures at roughly 19%–20% interest, and had not honored certain debenture and promissory-note repayments when due. Other financing disclosed includes 13% convertible debentures and 2024 secured notes at 17.5%, with interest-rate step-ups and potential equity dilution under specified terms.
- U.K. regulatory disruption: The FCA directed insurers to pause sales of Guaranteed Asset Protection (GAP) products in February 2024 pending approval of revised proposals. Roadzen describes GAP as a key contributor to U.K. operations and warns that delays or unfavorable outcomes could hurt revenue and margins.
- Operating and market risks: The company cites customer concentration, renewal and sales execution, competition, acquisition integration, regulatory compliance, foreign-exchange movements, cybersecurity and privacy, and dependence on third-party data and technology. It has no currency hedging arrangements.
- Guidance: The filing provides no specific financial guidance or quantified forecast. Management expects continued investment in technology, sales and marketing, and growth, with expenses expected to rise in absolute terms.
- Controls and legal matters: Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2024; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption. The company reported no material pending litigation.
Most important facts for investors to verify
- Whether the Mizuho debt was repaid, extended or refinanced after the July 31, 2024 waiver deadline, and the status of other overdue obligations.
- Whether the proposed funding arrangements exceeding $50 million closed, on what terms, and with what dilution, security interests or repayment obligations.
- The recoverability, timing and cash implications of the $28.8 million forward-purchase-agreement asset, including subsequent settlements and proceeds.
- The status of FCA approval and resumed GAP sales, and the resulting effect on U.K. revenue and profitability.
- Whether customer concentration, acquisition integration, receivable quality and operating cash use improved after year-end.
- The impact of RSU awards, warrants and convertible or secured financing on fully diluted shares and future financing capacity.